Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors

Empagliflozin belongs to a class of sodium-glucose cotransporter-2 inhibitors, a medication approved by the US Food and Drug Administration in 2014 for the treatment of type 2 diabetes mellitus. Well-known side effects of this medication include symptomatic hypotension, hypoglycemia, and urinary tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Dziadkowiec, Karolina N., Stawinski, Peter M., Proenza, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813547/
https://www.ncbi.nlm.nih.gov/pubmed/33490300
http://dx.doi.org/10.14309/crj.0000000000000530
Descripción
Sumario:Empagliflozin belongs to a class of sodium-glucose cotransporter-2 inhibitors, a medication approved by the US Food and Drug Administration in 2014 for the treatment of type 2 diabetes mellitus. Well-known side effects of this medication include symptomatic hypotension, hypoglycemia, and urinary tract infections among others. We present a case of severe epigastric abdominal pain consistent with acute pancreatitis in the setting of empagliflozin use, suggesting a possible drug-induced acute pancreatitis.

Ejemplares similares